Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).

Kasteleijn-Nolst Trenite DGA, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA.

Neurology. 2019 Aug 6;93(6):e559-e567. doi: 10.1212/WNL.0000000000007894. Epub 2019 Jul 10.

PMID:
31292226
2.

Normal Variants Are Commonly Overread as Interictal Epileptiform Abnormalities.

Kang JY, Krauss GL.

J Clin Neurophysiol. 2019 Jul;36(4):257-263. doi: 10.1097/WNP.0000000000000613.

PMID:
31274688
3.

Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy.

Johnson EL, Krauss GL, Lee AK, Schneider ALC, Kucharska-Newton AM, Huang J, Jack CR Jr, Gottesman RF.

Neurology. 2019 Feb 26;92(9):e988-e995. doi: 10.1212/WNL.0000000000007010. Epub 2019 Jan 25.

PMID:
30804067
4.

Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.

Johnson EL, Krauss GL, Lee AK, Schneider ALC, Dearborn JL, Kucharska-Newton AM, Huang J, Alonso A, Gottesman RF.

JAMA Neurol. 2018 Nov 1;75(11):1375-1382. doi: 10.1001/jamaneurol.2018.1935.

5.

Strategies for non-EEG seizure detection and timing for alerting and interventions with tonic-clonic seizures.

Gutierrez EG, Crone NE, Kang JY, Carmenate YI, Krauss GL.

Epilepsia. 2018 Jun;59 Suppl 1:36-41. doi: 10.1111/epi.14046. Review.

6.

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.

Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A.

Epilepsia. 2018 Apr;59(4):866-876. doi: 10.1111/epi.14044. Epub 2018 Mar 25.

7.

Non-EEG seizure detection is here.

Krauss GL, Ryvlin P.

Neurology. 2018 Jan 30;90(5):207-208. doi: 10.1212/WNL.0000000000004901. Epub 2018 Jan 5. No abstract available.

PMID:
29305440
8.

Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.

Kwok CS, Johnson EL, Krauss GL.

CNS Drugs. 2017 Nov;31(11):959-974. doi: 10.1007/s40263-017-0480-6. Review.

PMID:
29204953
9.

Optimal use of EEG montages to identify inferior temporal epileptiform activity.

Krauss GL, Lesser RP.

Clin Neurophysiol. 2018 Jan;129(1):280-281. doi: 10.1016/j.clinph.2017.10.021. Epub 2017 Nov 7. No abstract available.

PMID:
29174492
10.

Potential Influence of FDA-Sponsored Studies of Antiepilepsy Drugs on Generic and Brand-name Formulation Prescribing.

Krauss GL.

JAMA Neurol. 2017 Aug 1;74(8):900-901. doi: 10.1001/jamaneurol.2017.0492. No abstract available.

PMID:
28655026
11.

Regulating drivers with epilepsy in Maryland: Results of the application of a United States consensus guideline.

Ma BB, Bloch J, Krumholz A, Hopp JL, Foreman PJ, Soderstrom CA, Scottino MA, Matsumoto M, Krauss GL.

Epilepsia. 2017 Aug;58(8):1389-1397. doi: 10.1111/epi.13804. Epub 2017 Jun 1.

12.

More data on the safety of generic substitution: Yes, the blue tablet is OK?

Krauss GL, Privitera M.

Neurology. 2016 Oct 25;87(17):1754-1755. Epub 2016 Sep 28. No abstract available.

PMID:
27683849
13.

Evaluating and Treating Epilepsy Based on Clinical Subgroups: Elderly Onset Seizure and Medically Resistant Partial-Onset Epilepsy.

Johnson EL, Krauss GL.

Neurol Clin. 2016 Aug;34(3):595-610. doi: 10.1016/j.ncl.2016.04.004. Review.

PMID:
27445243
14.

Assessing bioequivalence of generic modified-release antiepileptic drugs.

Johnson EL, Chang YT, Davit B, Gidal BE, Krauss GL.

Neurology. 2016 Apr 26;86(17):1597-604. doi: 10.1212/WNL.0000000000002607. Epub 2016 Mar 25. Erratum in: Neurology. 2016 Jul 26;87(4):447.

15.

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.

French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, Trinka E, O'Brien TJ, Laurenza A, Patten A, Bibbiani F.

Neurology. 2015 Sep 15;85(11):950-7.

16.

Should "historic control" epilepsy monotherapy trials be "history"?

Krauss GL.

Epilepsy Curr. 2015 Jan-Feb;15(1):8-9. doi: 10.5698/1535-7597-15.1.8. No abstract available.

17.

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang X, Bagul M, Gee M, Zhu J, Squillacote D.

Epilepsia. 2014 Jul;55(7):1058-68. doi: 10.1111/epi.12643. Epub 2014 May 27.

18.

Epilepsy: responsive neurostimulation-modulating the epileptic brain.

Ben-Menachem E, Krauss GL.

Nat Rev Neurol. 2014 May;10(5):247-8. doi: 10.1038/nrneurol.2014.69. Epub 2014 Apr 22. No abstract available.

PMID:
24752127
19.

Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.

Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Laurenza A, Yang H, Zhu J, Squillacote D.

Epilepsia. 2014 Mar;55(3):423-31. doi: 10.1111/epi.12527. Epub 2014 Mar 7.

20.

Perampanel: a selective AMPA antagonist for treating seizures.

Krauss GL.

Epilepsy Curr. 2013 Nov;13(6):269-72. doi: 10.5698/1535-7597-13.6.269.

21.

Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol.

French JA, Krauss GL, Kasteleijn D, DiVentura BD, Bagiella E.

Neurotherapeutics. 2014 Apr;11(2):412-8. doi: 10.1007/s13311-013-0243-0.

22.

New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists.

Bell SG, Matsumoto M, Shaw SJ, Brandt J, Krauss GL.

Epilepsy Behav. 2013 Oct;29(1):36-40. doi: 10.1016/j.yebeh.2013.06.008. Epub 2013 Aug 7.

23.

Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials.

Hesdorffer DC, French JA, Posner K, DiVentura B, Pollard JR, Sperling MR, Harden CL, Krauss GL, Kanner AM.

Epilepsia. 2013 May;54(5):879-87. doi: 10.1111/epi.12128. Epub 2013 Feb 28.

24.

Overcoming barriers to successful epilepsy management.

Bateman LM, Begley CE, Ben-Menachem E, Berg AT, Berkovic SF, Cascino GD, Drazkowski J, Edwards JC, Engel J Jr, French JA, Gilliam FD, Hoerth MT, Jehi LE, Kanner AM, Krauss GL, Labiner DM, Loddenkemper T, Luders HO, McKhann GM 2nd, McLachlan R, Modi A, Pennell PB, Shafer PO, Sirven JI, Stern JM, Szaflarski JP, Theodore WH.

Epilepsy Curr. 2012 Jul;12(4):158-60. doi: 10.5698/1535-7511-12.4.158. No abstract available.

25.

Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, Kuba R, Squillacote D, Gee M, Kumar D.

Acta Neurol Scand. 2012 Oct;126(4):263-9. doi: 10.1111/ane.12001. Epub 2012 Aug 23.

PMID:
22913800
26.

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A.

Epilepsia. 2013 Jan;54(1):126-34. doi: 10.1111/j.1528-1167.2012.03648.x. Epub 2012 Aug 20.

27.

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.

Epilepsia. 2013 Jan;54(1):117-25. doi: 10.1111/j.1528-1167.2012.03638.x. Epub 2012 Aug 20.

28.

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA.

Neurology. 2012 Aug 7;79(6):589-96. doi: 10.1212/WNL.0b013e3182635735. Epub 2012 Jul 25.

29.

Which Hippocampal Sclerosis is Imaged With 7-T MRI?

Krauss GL.

Epilepsy Curr. 2012 May;12(3):99-100. doi: 10.5698/1535-7511-12.3.99. No abstract available.

30.

Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.

Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M.

Neuron. 2012 May 10;74(3):467-74. doi: 10.1016/j.neuron.2012.03.023.

31.

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A.

Neurology. 2012 May 1;78(18):1408-15. doi: 10.1212/WNL.0b013e318254473a. Epub 2012 Apr 18.

PMID:
22517103
32.

Stressful life event appraisal and coping in patients with psychogenic seizures and those with epilepsy.

Testa SM, Krauss GL, Lesser RP, Brandt J.

Seizure. 2012 May;21(4):282-7. doi: 10.1016/j.seizure.2012.02.002. Epub 2012 Mar 14.

33.

Lacosamide for the treatment of epilepsy.

Krauss GL, Edwards HB, Lin B.

Ann Med. 2012 Nov;44(7):674-9. doi: 10.3109/07853890.2011.603700. Epub 2012 Mar 1. Review.

PMID:
22380697
34.

Cognitive Activation of "Hyperexcitable Cortex" in JME: Can It Trigger Seizures?

Krauss GL.

Epilepsy Curr. 2011 Nov;11(6):184-5. doi: 10.5698/1535-7511-11.6.184. No abstract available.

35.

Treating patients with medically resistant epilepsy.

Krauss GL, Sperling MR.

Neurol Clin Pract. 2011 Dec;1(1):14-23. Erratum in: Neurol Clin Pract. 2012 Mar;2(1):4.

36.

Minimizing pharmacodynamic interactions of high doses of lacosamide.

Edwards HB, Cole AG, Griffiths AS, Lin B, Bean A, Krauss GL.

Acta Neurol Scand. 2012 Apr;125(4):228-33. doi: 10.1111/j.1600-0404.2011.01619.x. Epub 2011 Nov 10.

PMID:
22070525
37.

Registry initiated to characterize vision loss associated with vigabatrin therapy.

Pellock JM, Faught E, Sergott RC, Shields WD, Burkhart GA, Krauss GL, Foroozan R, Wesche DL, Weinberg MA.

Epilepsy Behav. 2011 Dec;22(4):710-7. doi: 10.1016/j.yebeh.2011.08.034. Epub 2011 Oct 5.

PMID:
21978471
38.

Tolerability and safety of perampanel: two randomized dose-escalation studies.

Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D.

Acta Neurol Scand. 2012 Jan;125(1):8-15. doi: 10.1111/j.1600-0404.2011.01588.x. Epub 2011 Aug 29.

PMID:
21883097
39.

Variation of seizure frequency with ovulatory status of menstrual cycles.

Herzog AG, Fowler KM, Sperling MR, Liporace JD, Kalayjian LA, Heck CN, Krauss GL, Dworetzky BA, Pennell PB; Progesterone Trial Study Group.

Epilepsia. 2011 Oct;52(10):1843-8. doi: 10.1111/j.1528-1167.2011.03194.x. Epub 2011 Jul 14.

40.

Personality Assessment Inventory among patients with psychogenic seizures and those with epilepsy.

Testa SM, Lesser RP, Krauss GL, Brandt J.

Epilepsia. 2011 Aug;52(8):e84-8. doi: 10.1111/j.1528-1167.2011.03141.x. Epub 2011 Jul 8.

41.

Assessing bioequivalence of generic antiepilepsy drugs.

Krauss GL, Caffo B, Chang YT, Hendrix CW, Chuang K.

Ann Neurol. 2011 Aug;70(2):221-8. doi: 10.1002/ana.22452. Epub 2011 Jun 29.

PMID:
21717495
42.

Evaluating risks for vigabatrin treatment.

Krauss GL.

Epilepsy Curr. 2009 Sep-Oct;9(5):125-9. doi: 10.1111/j.1535-7511.2009.01315.x.

43.

Re: Electrographic seizures and periodic discharges after intracerebral hemorrhage.

Krauss GL.

Neurology. 2008 Nov 4;71(19):1554; author reply 1554-5. No abstract available.

PMID:
18988336
44.

Generic antiepileptic drugs.

Shaw SJ, Krauss GL.

Curr Treat Options Neurol. 2008 Jul;10(4):260-8.

PMID:
18579013
45.

Cerebellar and thalamic stimulation treatment for epilepsy.

Krauss GL, Koubeissi MZ.

Acta Neurochir Suppl. 2007;97(Pt 2):347-56. Review.

PMID:
17691323
46.

Understanding and treating a channelopathy: severe myoclonic epilepsy of infancy.

Krauss GL, Morrison PF.

Neurology. 2007 Jul 17;69(3):233-4. No abstract available.

PMID:
17636058
47.

Pseudoseizure dogs.

Krauss GL, Choi JS, Lesser RP.

Neurology. 2007 Jan 23;68(4):308-9. No abstract available.

PMID:
17242342
48.

Clinical and EEG features of patients with EEG wicket rhythms misdiagnosed with epilepsy.

Krauss GL, Abdallah A, Lesser R, Thompson RE, Niedermeyer E.

Neurology. 2005 Jun 14;64(11):1879-83.

PMID:
15955937
50.

Supplemental Content

Loading ...
Support Center